IP Library › Granted Patent US 8,974,787
Granted Patent B2
US 8,974,787 · App. 13/889,608 · Granted Mar 10, 2015

Antagonistic human light-specific human monoclonal antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,974,787
App. No.
13/889,608
Granted
Mar 10, 2015
Kind
B2
Abstract

Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

Claims (20)

1. A method for treating or alleviating one or more symptoms of an inflammatory bowel disorder in a human subject, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that immunospecifically binds to human LIGHT (hLIGHT), wherein hLIGHT activity is inhibited by the antibody or antigen-binding fragment, and wherein the antibody or antigen-binding fragment thereof comprises: a variable heavy (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of GYNWH (SEQ ID NO:20); a VH CDR2 comprising the amino acid amino acid sequence of EITHSGSTNYNPSLKS (SEQ ID NO:21); and a VH CDR3 comprising the amino acid sequence of EIAVAGTGYYGMDV (SEQ ID NO:22): and a variable light (VL) CDR1 comprising the amino acid sequence of RASQGINSAFA (SEQ ID NO:35); a VL CDR2 comprising the amino acid sequence of DASSLES (SEQ ID NO:36); and a VL CDR3 comprising the amino acid sequence of QQFNSYPLT (SEQ ID NO:37).

2. The method of claim 1 , wherein the inflammatory bowel disorder is Crohn's disease.

3. The method of claim 1 , wherein the inflammatory bowel disorder is ulcerative colitis.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment is an antibody.

5. The method of claim 4 , wherein the antibody comprises a VH domain comprising the amino acid sequence of residues 20-141 of SEQ ID NO:4.

6. The method of claim 4 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of residues 20-141 of SEQ ID NO:4.

7. The method of claim 5 , wherein the antibody further comprises a VL domain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

8. The method of claim 5 , wherein the antibody further comprises a light chain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

9. The method of claim 6 , wherein the antibody further comprises a VL domain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

10. The method of claim 6 , wherein the antibody further comprises a light chain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

11. The method of claim 4 , wherein the antibody comprises a VL domain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

12. The method of claim 4 , wherein the antibody comprises a light chain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

13. The method of claim 1 , wherein the antibody or antigen-binding fragment is an antigen-binding fragment, and wherein the antigen-binding fragment comprises a VH domain comprising the amino acid sequence of residues 20-141 of SEQ ID NO:4.

14. The method of claim 1 , wherein the antibody or antigen-binding fragment is an antigen-binding fragment, and wherein the antigen-binding fragment comprises a heavy chain comprising the amino acid sequence of residues 20-141 of SEQ ID NO:4.

15. The method of claim 13 , wherein the antigen-binding fragment further comprises a VL domain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

16. The method of claim 13 , wherein the antigen-binding fragment further comprises a light chain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

17. The method of claim 14 , wherein the antigen-binding fragment further comprises a VL domain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

18. The method of claim 14 , wherein the antigen-binding fragment further comprises a light chain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

19. The method of claim 1 , wherein the antibody or antigen-binding fragment is an antigen-binding fragment, and wherein the antigen-binding fragment comprises a VL domain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

20. The method of claim 1 , wherein the antibody or antigen-binding fragment is an antigen-binding fragment, and wherein the antigen-binding fragment comprises a light chain comprising the amino acid sequence of residues 23-129 of SEQ ID NO:9.

Assignments (1)
CHANGE OF NAME AND ADDRESS Recorded Oct 23, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050797/0533 →